Pathways and gene expression profiles in hepatocellular carcinoma

Minerva Gastroenterologica e Dietologica

Volumn 58, Issue 1, 2012, Pages 35-47

  Facciorussso, A ^a   Naccchiero, M C ^a   Rosania, R ^a   Laonigro, G ^a   Giorgio, F ^a   Del Prete, V ^a   Panella, C ^a   Ierardi, E ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Carcinoma, hepatocellular; Chromosome aberrations; Phenotype

Indexed keywords

AFLATOXIN; ANDROGEN RECEPTOR; BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PROTEIN P53; RETINOBLASTOMA PROTEIN; SECURIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL CONSUMPTION; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANGIOGENESIS; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CHROMOSOME ABERRATION; CHRONIC HEPATITIS; CHRONIC INFLAMMATION; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; GAIN OF FUNCTION MUTATION; GENE EXPRESSION PROFILING; GENE MUTATION; HEMOCHROMATOSIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNITY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MICROSATELLITE INSTABILITY; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; WNT SIGNALING PATHWAY;

CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPACIVIRUS; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MUTATION; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84860283100     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma - epidemiological trends and risk factors. Dig Dis 2009;27:80-92.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6. (Pubitemid 32911406)
3. Teo EK, Fock KM. Hepatocellular carcinoma: an Asian perspective. Dig Dis 2001;19:263-8 (Pubitemid 34297993)
4. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40 Suppl 1:S5-S10. (Pubitemid 44309537)
5. Smela ME, Currier SS, Bailey EA, Essigmann JM. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis 2001;22:535-45. (Pubitemid 32288652)
6. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-31. (Pubitemid 21912246)
7. Kew MC. Hepatic iron overload and hepatocellular carcinoma. Cancer Lett 2009;286:38-43.
8. Barone M, Margiotta M, Scavo MP, Gentile A, Francioso D, Papagni S et al. Possible involvement of androgen receptor alterations in hepatocarcinogenesis. Dig Liver Dis 2009;41:665-70.
9. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-46. (Pubitemid 35154440)
10. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002;13:1929-39. (Pubitemid 34651483)
11. Ferrell LD, Crawford JM, Dhillon AP, Scheuer PJ, Nakanuma Y. Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol 1993;17:1113-23. (Pubitemid 23313785)
12. Roncalli M. Hepatocellular nodules in cirrhosis: focus on diagnostic criteria on liver biopsy. A Western experience. Liver Transpl 2004;10:S9-S15. (Pubitemid 38240093)
13. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10:185-200. (Pubitemid 30614220)
14. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005;25:133-42. (Pubitemid 40781066)
15. Hoshida Y, Toffanin S, Lackenmayer A, Villanueva A, Minquez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51.
16. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992;52:6358-64.
17. Tsuda H, Hirohashi S, Shimosato Y, Yno Y, Yoshida T, Terada M. Low incidence of point mutation of c-Kiras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res 1989;80:196-9. (Pubitemid 20027206)
18. Boix L, Rosa JL, Ventura F, Castells A, Bruix J, Rodès J et al. c-met mRNA expression in human hepatocellular carcinoma. Hepatology 1994;19:88-91. (Pubitemid 24020476)
19. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006;25:3778-86. (Pubitemid 43980473)
20. Zhang X, Xu HJ, Murakami Y, Sachse R, Yashima K, Hirohashi S et al. Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177-82. (Pubitemid 24258127)
21. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
22. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
23. Yoshiura K, Kanai Y, Ochiai A, Shimoyama J, Sugimura T, Hirohashi S. Silencing of the E-cadherin invasionsuppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci U S A 1995;92:7416-9.
24. Cheah MS, Wallace CD, Hoffman RM. Hypomethylation of DNA in human cancer cells:a site-specific change in the c-myc oncogene. J Natl Cancer Inst 1984;73.1057-65.
25. El-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci U S A 1991;88:3470-4. (Pubitemid 21916643)
26. Sun L, Hui AM, Kanai Y, Sakamoto M, Hirohashi S. Increased DNA methyltransferase expression is associated with an early stage of human hepatocarcinogenesis. Jpn J Cancer Res 1998;88:1165-70.
27. Kanai Y, Hui AM, Sun L, Ushijima S, Sakamoto M, Tsuda H et al. DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 1999;29:703-9. (Pubitemid 29109583)
28. MacLeod AR, Szyf M. Expression of antisense to DNA methyltransferase mRNA induces DNA methylation and inhibits tumorigenesis. J Biol Chem 1995;270:8037-43
29. Ramchandani S, MacLeod AR, Pinard M, von Hofe E, Szyf M. Inhibition of tumorigenesis by a cytosine DNA, methyltransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A 1997;94:684-9. (Pubitemid 27053694)
30. Salvucci M, Lemoine A, Saffroy R, Azoulay D, Lepère B, Gaillard S. Microsatellite instability in European hepatocellular carcinoma. Oncogene 1999;18:181-7. (Pubitemid 29060592)
31. Kazachkov Y, Yoffe B, Khaoustov VI, Salomon H, Klintmalm GB, Tabor E. Microsatellite instability in human hepatocellular carcinoma: relationship to p53 abnormalities. Liver 1998;18:156-61. (Pubitemid 28368064)
32. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschi T. Identification of novel genes encoding for small expressed RNAs. Science 2001;294:853-8. (Pubitemid 33032103)
33. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probably regulatory roles in Caenorhabditis elegans. Science 2001;294:858-62. (Pubitemid 33032104)
34. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003;113:673-6. (Pubitemid 36724931)
35. Gregory RJ, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res 2005;65:3509-12. (Pubitemid 40616320)
36. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A et al. Identification of metastasis-related micro-RNAs in hepatocellular carcinoma. Hepatology 2008;47:897-907. (Pubitemid 351449681)
37. Ji J, Shi J, Budhu A, Yu Z, Forques M, Roessler S et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009;361:1437-47.
38. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-73. (Pubitemid 32523494)
39. Katoh H, Ojima H, Kokubu A, Saito S, Kondo T, Kosuge T et al. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology 2007;133:1475-86. (Pubitemid 350029748)
40. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34. (Pubitemid 44286004)
41. Boyault S, Richman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52. (Pubitemid 46144363)
42. Lee J-S, Chu I-S, Heo J, Calvisi DF, Sun Z, Roskams T et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-76. (Pubitemid 39265589)
43. Thorgeirsson SS, Lee J-S, Grisham JW. Functional genomics of hepatocellular carcinoma. Hepatology 2006;43:S145-50.
44. Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 2006;25:3801-9. (Pubitemid 43980475)
45. Katoh H, Shibata T, Kokubu A, Ojima H, Fukuyama M, Kanai Y et al. Epigenetic instability and chromosomal instability in hepatocellular carcinoma. Am J Pathol 2006;168:1375-84.
46. Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S et al. The critical issue of hepatocellular carcinomaprognostic classification: which is the best tool available? J Hepatol 2004;40:124-31. (Pubitemid 38064721)
47. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004
48. Budhu A, Forgues M, Ye Q-H, Jia HL, He P, Zanetti KA et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111. (Pubitemid 44202603)
49. Branda M, Wands JR. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 2006;43:891-902. (Pubitemid 43724611)
50. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-6.
51. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minquez B et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008;68:6779-88.
52. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-90. (Pubitemid 27136715)
53. de la Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O et al. Somatic mutations of the betacatenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998;95:8847-51. (Pubitemid 28350577)
54. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763-70.
55. Huang H, Fujii H, Sankila A, Mahler-Araujo BM, Matsuda M, Cathomas G et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C infection. Am J Pathol 1999;155:1795-801.
56. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25:212-25 (Pubitemid 40781073)
57. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signaling pathways in cancer. Oncogene 2007;26:3279-90. (Pubitemid 46763021)
58. Newell P, Toffanin S, Villanueva A, Chiang DY, Minquez B, Cabellos L et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009;51:725-33.
59. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
60. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48:S20-37.
61. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25:212-25. (Pubitemid 40781073)
62. Villanueva A, Chiang DK, Newell P, Peix J, Thung S, Alsinet C et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-83.
63. Rizell M, Andersson M, Cahlin C, Hafstrom L, Olausson M, Lindnèr P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 2008;13:66-70. (Pubitemid 351326289)
64. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinomas weighty connection. Hepatology 2010;51:1820-32.
65. Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Solè M et al. IGF activation in a molecular subclass hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010;52:550-9.
66. El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. (Pubitemid 46890874)
67. Buckley AF, Burgart LJ, Sahai V, Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 2008;129:245-51. (Pubitemid 352029315)
68. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005;41:307-14. (Pubitemid 40165374)
69. Kim KR, Moon HE, Kim KW Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med 2002;80:703-14
70. Sanz-Cameno O, Trapero-Marugan M, Chaparro M, Jones EA, Moreno-Otero R. Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol 2010;2010:272170
71. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998;28:68-77. (Pubitemid 28299987)
72. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103:914-21. (Pubitemid 351506379)
73. Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008;47:2059-67. (Pubitemid 351945572)
74. Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology 2009;49(Suppl 5):S56-60.
75. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 2009;1155:206-21.
76. Hagen TM, Huang S, Curnutte J, Fowler P, Martinez V, Wehr CM et al. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci U S A 1994;91:12808-12.
77. Fujita N, Sugimoto R, Ma N, Tanaka H, Iwasa M, Kobayashi Y et al. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J Viral Hepat 2008;15:498-507. (Pubitemid 351798987)
78. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010;29:2309-24.
79. Madhoun MF, Fazili J, Bright BC, Bader T, Roberts DN, Bronze MS. Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis. Am J Med Sci 2010;339:169-73.
80. Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett 2007;252:157-70. (Pubitemid 46809787)
81. Cougot D, Neuveut C, Buendia MA. HBV induced carcinogenesis. J Clin Virol 2005;34(Suppl 1):S75-8.
82. Brechot C, Kremsdorf D, Soussan P, Pineau P, Dejean A, Paterlini-Brechot P et al. Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC):Molecular mechanisms and novel paradigms. Pathol Biol (Paris) 2010;58:278-87.
83. Yun C, Cho H, Kim SJ, Lee JH, Park SY, Chan GK et al. Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogenactivated protein pathway. Mol Cancer Res 2004;2:159-69. (Pubitemid 39030306)
84. Kim S, Park SY, Yong H, Famulski JK, Chae S, Lee JH et al. HBV X protein targets hBubRl, which induces dysregulation of the mitotic checkpoint. Oncogene 2008;27:3457-64. (Pubitemid 351769311)
85. Molina-Jimenez F, Benedicto I, Murata M, Martìn-Vilchez S, Seki T, Antonio Pintotr-Toro J et al. Expression of pituitary tumortransforming gene 1 (PTTG1)/securin in hepatitis B virus (HBV)-associated liver diseases: evidence for an HBV X protein-mediated inhibition of PTTG1 ubiquitination and degradation. Hepatology 2010;51:777-87.
86. Ghebranious N, Sell S. The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice. Hepatology 1998;27:967-73. (Pubitemid 28160481)
87. Kwun HJ, Jung EY, Ahn JY, Lee MN, Jang KL. p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J Gen Virol 2001;82:2235-41. (Pubitemid 32827604)
88. Ray RB, Lagging LM, Meyer K, Steele R, Ray R. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995;37:209-20.